An open-label pilot study on the effects of trivalent inactivated influenza vaccination (Influvac®) in patients with hypo- and dysgammaglobulinemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN31814323

Enrollment

100

Registered

2006-12-28

Start date

2006-10-01

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypo- or Dysgammaglobulinemia Haematological Disorders Immunodeficiency

Interventions

Vaccination with trivalent inactivated influenza vaccine (Influvac®)

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients have to fulfil the diagnostic criteria for primary immunodeficiency as defined by the Pan-American Group for Immunodeficiency and the European Society for immunodeficiencies 2. Informed consent

Exclusion criteria

Exclusion criteria: 1. Age under 18 years 2. Current infection, defined as fever in combination with clinical focal signs of infection and the need for therapeutic antibiotic treatment 3. Pregnancy 4. Malignancy 5. Continuous use of immunosuppressive drugs 6. Known allergy to any substance of Influvac®

Design outcomes

Primary

Measure	Time frame
Cellular immune responses	—

Secondary

Measure	Time frame
1. Humoral immune responses 2. Side effects	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026